Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

376.81USD
10:09am EST
Change (% chg)

$1.31 (+0.35%)
Prev Close
$375.50
Open
$377.55
Day's High
$381.13
Day's Low
$374.30
Volume
28,508
Avg. Vol
260,843
52-wk High
$416.49
52-wk Low
$281.89

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $50,356.19
Shares Outstanding(Mil.): 107.15
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 47.17 69.72 34.40
EPS (TTM): 9.96 -- --
ROI: 18.73 9.00 14.96
ROE: 24.06 10.14 16.53

New drug options, risk factors added to U.S. heart guidelines

Updated U.S. guidelines on heart health advise more personalized assessment of risk as well as two newer types of cholesterol-lowering drugs for people at particularly high risk of heart attack or stroke.

Nov 10 2018

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Nov 06 2018

UPDATE 1-Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Nov 06 2018

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA - companies

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator gave more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Nov 06 2018

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

Oct 31 2018

UPDATE 2-Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS, Oct 31 Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

Oct 31 2018

Regeneron wins dismissal of willfulness claim in Eylea patent dispute

Regeneron Pharmaceuticals Inc has won dismissal of Novartis AG's claim that two of its biologic drugs willfully infringed a now-expired patent on gene expression technology.

Oct 25 2018

FDA declines to approve pre-filled syringe version of Regeneron's Eylea

Regeneron Pharmaceuticals Inc said on Thursday the U.S. Food and Drug Administration declined to approve a pre-filled syringe version of its blockbuster eye drug Eylea, and has sought additional information regarding its manufacturing and supply processes.

Oct 25 2018

U.S. FDA declines to approve pre-filled syringe version of Regeneron's Eylea

Oct 25 Regeneron Pharmaceuticals Inc said on Thursday the U.S. Food and Drug Administration declined to approve a pre-filled syringe version of its blockbuster eye drug Eylea, and has sought additional information regarding its manufacturing and supply processes.

Oct 25 2018

UPDATE 1-Amgen cuts U.S. price of cholesterol drug Repatha by 60 percent

Oct 24 Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.

Oct 24 2018

Earnings vs. Estimates